NuScale Power (NYSE: SMR) has endured a brutal twelve months, with shares falling 81.9%, placing the stock firmly in recovery-story territory for investors assessing a fresh entry point.
Despite that steep decline, the company scores just 1 out of 6 on broader valuation checks, suggesting the stock leans expensive rather than offering an obvious bargain at current levels.
The share price drop does reflect significant pessimism already baked in, but weak valuation scores argue against treating NuScale as a straightforward value play.
NuScale’s small modular reactor technology is positioned as a potential answer to surging energy demand driven by artificial intelligence infrastructure buildout across the United States.
At the same time, the ENTRA1 probe and resulting fraud lawsuits have clouded investor confidence in management’s ability to execute on the commercial side of its business.
On a price-to-book basis, NuScale currently trades at a P/B multiple of 2.6x, sitting very close to the electrical industry average of approximately 2.5x.
That alignment with sector peers suggests the market is pricing NuScale’s equity in line with comparable companies rather than assigning a meaningful discount or premium to its balance sheet.
For investors, that points to a valuation driven more by execution risk and the SMR rollout narrative than by any clear gap between price and book value.
Community views on the stock remain sharply divided, with bulls highlighting NuScale’s NRC-approved technology and over $2 billion committed toward its development and licensing as evidence the company is “uniquely positioned for immediate commercial deployment compared to competitors focused solely on demonstration plans.”
Bears counter that “the ENTRA1 controversy and the resulting fraud lawsuits are serious,” raising questions about whether management can translate strong engineering credentials into reliable commercial execution.
The gap between the bull case, which sees the stock as 43% undervalued, and the bear case, which places it at 972% overvalued, illustrates just how wide the range of outcomes remains for NuScale at this stage.
From here, the central question is whether NuScale can convert its SMR pipeline into binding contracts and meaningful cash flows that justify today’s pricing despite persistent legal and governance risks.
Investors’ individual assessments of that execution risk will ultimately determine whether the current valuation looks appropriately cautious or dangerously generous given the company’s pre-revenue stage.
